Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Conditions
Metastatic Digestive System Neuroendocrine Tumor G1 · Metastatic Digestive System Neuroendocrine Tumor G2 · Unresectable Digestive System Neuroendocrine Tumor G1 · Unresectable Digestive System Neuroendocrine Tumor G2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Contact: Principal Investigator (Patrick W. McGarrah)Banner University Medical Center - Tucson, Tucson, Arizona, United States
Contact: Principal Investigator (Rachna T. Shroff)University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Contact: Principal Investigator (Rachna T. Shroff)UCHealth University of Colorado Hospital, Aurora, Colorado, United States
Contact: Principal Investigator (Emily Baiyee-Toegel)UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
Contact: Principal Investigator (Gretel Terrero)UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Contact: Principal Investigator (Gretel Terrero)UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
Contact: Principal Investigator (Gretel Terrero)Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Principal Investigator (Patrick W. McGarrah)University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Contact: Principal Investigator (Gretel Terrero)UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
Contact: Principal Investigator (Gretel Terrero)University of Miami Sylvester Comprehensive Cancer Center at Sole Mia, North Miami, Florida, United States
Contact: Principal Investigator (Gretel Terrero)UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
Contact: Principal Investigator (Gretel Terrero)Northwestern University, Chicago, Illinois, United States
Contact: Principal Investigator (Al B. Benson)University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222Contact: Principal Investigator (Chih-Yi Liao)Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States
Contact: Principal Investigator (Al B. Benson)Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States
Contact: Principal Investigator (Al B. Benson)UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222Contact: Principal Investigator (Chih-Yi Liao)University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222Contact: Principal Investigator (Chih-Yi Liao)Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
Contact: Principal Investigator (Al B. Benson)UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa, United States
Contact: Principal Investigator (Seema Harichand-Herdt)UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive, Iowa, United States
Contact: Principal Investigator (Seema Harichand-Herdt)Iowa Methodist Medical Center, Des Moines, Iowa, United States
Contact: Principal Investigator (Seema Harichand-Herdt)UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines, Iowa, United States
Contact: Principal Investigator (Seema Harichand-Herdt)UI Health Care Mission Cancer and Blood - Laurel Clinic, Des Moines, Iowa, United States
Contact: Principal Investigator (Seema Harichand-Herdt)UI Health Care Mission Cancer and Blood - Waukee Clinic, Waukee, Iowa, United States
Contact: Principal Investigator (Seema Harichand-Herdt)University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Henry Ford Hospital, Detroit, Michigan, United States
Contact: Principal Investigator (Gazala Khan)Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Principal Investigator (Patrick W. McGarrah)University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
University of Rochester, Rochester, New York, United States
Contact: Principal Investigator (Haoming Qiu)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Contact: Principal Investigator (Heloisa P. Soares)BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Contact: Principal Investigator (Jonathan M. Loree)CancerCare Manitoba, Winnipeg, Manitoba, Canada
Doctor H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
Contact: Principal Investigator (Renee Lester)London Regional Cancer Program, London, Ontario, Canada
Contact: Principal Investigator (David Laidley)Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada
Contact: Principal Investigator (Timothy R. Asmis)Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Contact: Principal Investigator (Simron Singh)
Study leads
Simron Singh
Principal Investigator
Canadian Cancer Trials Group